These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39053611)

  • 1. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
    King B; Senna MM; Mesinkovska NA; Lynde C; Zirwas M; Maari C; Prajapati VH; Sapra S; Brzewski P; Osman L; Hanna S; Wiseman MC; Hamilton C; Cassella J
    J Am Acad Dermatol; 2024 Nov; 91(5):880-888. PubMed ID: 39053611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
    King B; Mesinkovska N; Mirmirani P; Bruce S; Kempers S; Guttman-Yassky E; Roberts JL; McMichael A; Colavincenzo M; Hamilton C; Braman V; Cassella JV
    J Am Acad Dermatol; 2022 Aug; 87(2):306-313. PubMed ID: 35364216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
    N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis.
    Barati Sedeh F; Michaelsdóttir TE; Henning MAS; Jemec GBE; Ibler KS
    Acta Derm Venereol; 2023 Jan; 103():adv00855. PubMed ID: 36695751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
    Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
    JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
    King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
    J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
    King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
    J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
    Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
    J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.
    King B; Ko J; Kwon O; Vañó-Galván S; Piraccini BM; Dutronc Y; Yu G; Liu C; Somani N; Ball S; Mesinkovska NA
    JAMA Dermatol; 2024 Oct; 160(10):1075-1081. PubMed ID: 39141364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
    Gupta AK; Wang T; Polla Ravi S; Bamimore MA; Piguet V; Tosti A
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):666-679. PubMed ID: 36478475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
    Hordinsky M; Hebert AA; Gooderham M; Kwon O; Murashkin N; Fang H; Harada K; Law E; Wajsbrot D; Takiya L; Zwillich SH; Wolk R; Tran H
    Pediatr Dermatol; 2023; 40(6):1003-1009. PubMed ID: 37455588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib for the Treatment of Alopecia Areata.
    Freitas E; Guttman-Yassky E; Torres T
    Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel investigational drugs for alopecia areata and future perspectives.
    Chim I; Ghiya R; Sinclair RD; Eisman S
    Expert Opin Investig Drugs; 2024 May; 33(5):441-449. PubMed ID: 38682280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
    Eisman S; Sinclair R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
    Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
    JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.